Journal
ENDOCRINE-RELATED CANCER
Volume 21, Issue 4, Pages T219-T234Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-13-0508
Keywords
estrogen receptor beta; prostate; cancer; androgen; estrogen
Categories
Funding
- Medical Research Council [MR/L00156X/1]
- Urology Foundation Scholarship [RESCH1302]
- National Health and Medical Research Council of Australia [627185]
- Cancer Australia [627229]
- Prostate Cancer Foundation of Australia
- Cancer Research UK
- Medical Research Council
- National Institute for Health Research
- ERC starting grant
- EMBO Young investigator award
- MRC [MR/L00156X/1] Funding Source: UKRI
- Cancer Research UK [15602] Funding Source: researchfish
- Medical Research Council [MR/L00156X/1] Funding Source: researchfish
- The Urology Foundation [RESCH1302] Funding Source: researchfish
Ask authors/readers for more resources
Prostate cancer is the commonest, non-cutaneous cancer in men. At present, there is no cure for the advanced, castration-resistant form of the disease. Estrogen has been shown to be important in prostate carcinogenesis, with evidence resulting from epidemiological, cancer cell line, human tissue and animal studies. The prostate expresses both estrogen receptor alpha (ERA) and estrogen receptor beta (ERB). Most evidence suggests that ERA mediates the harmful effects of estrogen in the prostate, whereas ERB is tumour suppressive, but trials of ERB-selective agents have not translated into improved clinical outcomes. The role of ERB in the prostate remains unclear and there is increasing evidence that isoforms of ERB may be oncogenic. Detailed study of ERB and ERB isoforms in the prostate is required to establish their cell-specific roles, in order to determine if therapies can be directed towards ERB-dependent pathways. In this review, we summarise evidence on the role of ERB in prostate cancer and highlight areas for future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available